ABVC BioPharma, Inc. (NASDAQ: ABVC) reported financial results for the quarter ended September 30, 2025, highlighting a 230% year-over-year increase in licensing revenue to approximately USD 1.28 million, compared to USD 0.39 million in the same period of 2024. The company also saw total assets grow by 181% to USD 21.18 million, up from USD 7.54 million at the end of 2024. Property and equipment surged by approximately 2,100% to USD 12.06 million, reflecting recent real-asset investments in Taiwan.
The revenue growth was driven by the company's licensing programs covering central nervous system (CNS), ophthalmology, and oncology/hematology indications. ABVC continues to follow an asset-light business model focused on licensing, partnerships, and collaborative development, but recent investments in physical assets are expected to enhance future research and manufacturing capacity.
During the third quarter, ABVC completed two land acquisitions in Taiwan totaling approximately USD 11 million. AiBtl BioPharma Inc., a subsidiary, acquired land in Puli (Nantou) for USD 7.67 million to develop a plant factory for botanical raw materials and new drug substance research. Separately, ABVC BioPharma acquired land in Longtan (Taoyuan) for USD 3.3 million for agricultural R&D and API cultivation. These investments, together with the planned Vitargus® GMP manufacturing facility, are expected to strengthen the company's Asia-based production and research capabilities.
ABVC maintains a global dual-core structure, with operations in Silicon Valley focusing on innovation and clinical development through its BioKey platform, and Taiwan supporting manufacturing and development activities. The company's pipeline includes six drugs and one medical device (ABV-1701/Vitargus®) under development, utilizing in-licensed technology from research institutions such as Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center.
Dr. Uttam Patil, ABVC's Chief Executive Officer, stated, 'Our third-quarter results reflect continued progress in both our licensing revenue and asset development activities. We remain focused on executing our strategic priorities to create sustainable value for our shareholders over the long term.'
The company's licensing agreements provide potential future milestone and royalty income based on development and commercialization progress. ABVC seeks to advance its key pipeline assets and explore additional partnerships to support its long-term growth strategy.
Forward-looking statements in this press release involve risks and uncertainties, including those related to manufacturing, financing, competition, and regulatory approvals. More detailed information is available in the company's filings with the SEC at http://www.sec.gov.
